PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.14
D/E of 0.14 versus zero Biotechnology median. Walter Schloss would verify if our leverage provides competitive advantages.
4.63
Dangerously high net debt exceeding 1.5x Biotechnology median of 1.64. Michael Burry would check for debt covenant compliance and refinancing risks.
-3518.20
Negative coverage while Biotechnology median is 0.00. Seth Klarman would scrutinize operating performance and look for turnaround catalysts.
1.20
Current ratio 50-75% of Biotechnology median of 1.74. Martin Whitman would look for hidden assets or working capital optimization.
No Data
No Data available this quarter, please select a different quarter.